Literature DB >> 31515159

Clinical implications of multiple glioblastomas: An analysis of prognostic factors and survival to distinguish from their single counterparts.

Li-Tsun Shieh1, How-Ran Guo2, Yu-Kang Chang3, Na-Mi Lu4, Sheng-Yow Ho5.   

Abstract

PURPOSE: Glioblastoma (GBM) has the highest fatality rate among primary malignant brain tumors. GBMs with synchronous multiple foci (multiple GBMs) is rarely diagnosed in the clinical scenario. This study aims to compare the clinical characteristics between multiple and single GBMs and to identify factors associated with the survival of GBM and evaluate their effects.
METHODS: We retrospectively reviewed the medical records of patients with primary GBM in a referral medical center in Taiwan who were diagnosed between 2005 and 2016. They were identified from the cancer registry database of the center and followed from the date of diagnosis to october 2018. The primary endpoint of this study was overall survival (OS), and the independent factors for survival were identified through Cox regressions.
RESULTS: A total of 48 patients were identified, of whom 44 GBM (92%) and 4 gliosarcoma (GSM) (8%). Preoperative images showed five (10%) patients had multiple brain lesions. GSM showed a high ratio of multiple lesions (50%) than patients with GBM (5%) (p = 0.05). Those with multiple lesions had significantly worse median OS of 8.2 months compared to patients with a single lesion (16 months, p = 0.03). We found that multiple GBMs was a predictor of worse survival (hazard ratio [HR] = 3.57, 95% confidence interval [95%CI]: 1.26-10.13) after adjusting for other significant predictor of radiotherapy (HR = 0.47, 95%CI: 0.23-0.96).
CONCLUSION: Patients with multiple GBMs had worse survival compared to those with single GBM. GBM patients without post-operative radiotherapy were also a predictor of worse survival.
Copyright © 2019 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glioblastoma; Gliosarcoma; Multiple brain lesions; Radiotherapy; Survival

Mesh:

Year:  2019        PMID: 31515159     DOI: 10.1016/j.jfma.2019.08.024

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  6 in total

1.  Nuclear respiratory factor 1 transcriptomic signatures as prognostic indicators of recurring aggressive mesenchymal glioblastoma and resistance to therapy in White American females.

Authors:  Kaumudi Bhawe; Jayanta K Das; Changwon Yoo; Quentin Felty; Zhenghua Gong; Alok Deoraj; Juan P Liuzzi; Nasreen Z Ehtesham; Seyed E Hasnain; Varindera Paul Singh; Ishani Mohapatra; Ricardo Jorge Komotar; Deodutta Roy
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-20       Impact factor: 4.553

Review 2.  Epidemiology of Glioblastoma Multiforme-Literature Review.

Authors:  Szymon Grochans; Anna Maria Cybulska; Donata Simińska; Jan Korbecki; Klaudyna Kojder; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

3.  Patient specific, imaging-informed modeling of rhenium-186 nanoliposome delivery via convection-enhanced delivery in glioblastoma multiforme.

Authors:  Ryan T Woodall; David A Hormuth Ii; Chengyue Wu; Michael R A Abdelmalik; William T Phillips; Ande Bao; Thomas J R Hughes; Andrew J Brenner; Thomas E Yankeelov
Journal:  Biomed Phys Eng Express       Date:  2021-05-28

Review 4.  Epidemiology of Anthropometric Factors in Glioblastoma Multiforme-Literature Review.

Authors:  Donata Simińska; Jan Korbecki; Klaudyna Kojder; Patrycja Kapczuk; Marta Fabiańska; Izabela Gutowska; Anna Machoy-Mokrzyńska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Brain Sci       Date:  2021-01-16

5.  Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database.

Authors:  Li-Tsun Shieh; Chung-Han Ho; How-Ran Guo; Chien-Cheng Huang; Yi-Chia Ho; Sheng-Yow Ho
Journal:  Front Neurol       Date:  2021-11-24       Impact factor: 4.003

6.  Survival of glioblastoma treated with a moderately escalated radiation dose-Results of a retrospective analysis.

Authors:  Li-Tsun Shieh; How-Ran Guo; Chung-Han Ho; Li-Ching Lin; Chin-Hong Chang; Sheng-Yow Ho
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.